Pro zobrazení tohoto obsahu je třeba být přihlášen.
Author Archives for m.popovic@wemakemedia.cz
Pregnancy Management in CML Patients: To Treat or Not to Treat? Report of 224 Outcomes of the European Leukemia Net (ELN) Database
25 února, 2021 5:17 pm Leave your thoughtsProgram: Oral and Poster Abstracts Type: Oral Session: 632. Chronic Myeloid Leukemia: Therapy: Clinical Trials and Outcomes ...
Chronická myelocytová leukémia – novinky z výročnej konferencie ASH® 2019
25 února, 2021 5:11 pm Leave your thoughtsŠesťdesiata prvá výročná konferencia Americkej hematologickej spoločnosti (posledná v tomto desaťročí) – v skratke ASH® 2019 – sa konala od 7. do 10. 12....
Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study
25 února, 2021 5:04 pm Leave your thoughtsProgram: Oral and Poster Abstracts Type: Oral Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, excluding Transplantation: Induction...
Response to Sorafenib in FLT3/ITD AML Is Depedent on Co-Occurring Mutational Profile
25 února, 2021 4:56 pm Leave your thoughtsProgram: Oral and Poster Abstracts Type: Oral Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Induction...
Patterns of Care and Clinical Outcomes with 7 + 3 Induction Chemotherapy for Patients (pts) with Acute Myeloid Leukemia (AML) in the United States (US): A Large Population-Based Study
25 února, 2021 4:47 pm Leave your thoughtsProgram: Oral and Poster Abstracts Type: Oral Session: 615. Acute Myeloid Leukemia: Commercially Available Therapy, Excluding Transplantation: Induction...
leukemie
25 února, 2021 4:40 pm Leave your thoughtsKonference Americké hematologické společnosti ASH® 2019, jež se konala v Orlandu na Floridě, představila algoritmus terapie akutní myeloidní leukemie (AML). V oblastech molekulární...
Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia
25 února, 2021 4:36 pm Leave your thoughtsProgram: Oral and Poster Abstracts Type: Oral Session: 311. Disorders of Platelet Number or Function: Advances in ITP...
Phase II Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia
25 února, 2021 4:29 pm Leave your thoughtsProgram: Oral and Poster Abstracts Type: Oral Session: 311. Disorders of Platelet Number or Function: Advances in ITP...
Phase I/II, Open-Label, Adaptive Study of Oral Bruton Tyrosine Kinase Inhibitor PRN1008 in Patients with Relapsed/Refractory Primary or Secondary Immune Thrombocytopenia
25 února, 2021 4:23 pm Leave your thoughtsProgram: Oral and Poster Abstracts Type: Oral Session: 311. Disorders of Platelet Number or Function: Clinical Insights into...
Imunitní trombocytopenie – zajímavosti z ASH®
25 února, 2021 4:14 pm Leave your thoughtsV rámci každoročního kongresu Americké hematologické společnosti, který se konal ve dnech 7.–10. prosince 2019 v Orlandu na Floridě (Spojené státy americké)...